Atorvastatin Sandoz

Atorvastatin Sandoz Indications/Uses

atorvastatin

Manufacturer:

Sandoz

Distributor:

Zuellig Pharma

Marketer:

Novartis
Full Prescribing Info
Indications/Uses
Hypercholesterolaemia: Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
Atorvastatin is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
Prevention of cardiovascular disease: Atorvastatin is used to prevent cardiovascular events in patients without clinical evidence of cardiovascular disease who have multiple risk factors for a first cardiovascular event (see Pharmacology: Pharmacodynamics under Actions), as an adjunct to correction of other risk factors
Chronic Kidney Disease: In patients with diabetes with moderately decreased estimated glomerular filtration rate (eGFR), atorvastatin is indicated to reduce the risk for cardiovascular disease. In patients with clinically evident coronary heart disease and CKD not requiring dialysis, atorvastatin is indicated to reduce the risk of major cardiovascular events including stroke. In patients with clinically evident coronary heart disease and/or diabetes with microalbuminuria, atorvastatin is indicated to reduce the rate of GFR decline and progression of CKD
Paediatric Patients (10-17 years of age): Atorvastatin is indicated as adjunct to diet to reduce total cholesterol, LDL-C and apo B levels in boys and post-menarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and There is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the paediatric patient
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in